President Donald Trump turned up the heat on his own team Saturday, politely but firmly asking if they would finish rescheduling cannabis just four months after his order. In the Oval Office, with podcaster Joe Rogan right behind him, Trump said, “Will you get the rescheduling done, please? They’re slow-walking me.” This came as he signed a new order to speed up research on psychedelics for mental health.
Trump made his plea during a busy Oval Office moment on April 18. He looked straight at officials and repeated his question twice. “You’re going to get the rescheduling done, right, please?” he pressed.
This follows his earlier directive to the Department of Justice. Cannabis sits in Schedule I now, meaning the government sees no medical use and high abuse risk. Moving it to Schedule III would change that view big time.
Health experts say this shift could unlock new research paths.
Federal data shows over 2.5 million cannabis arrests since 2001, per the ACLU. Many states already allow medical or full use.
Psychedelics Get a Major Boost Too
Trump signed an executive order to fast-track studies on drugs like ibogaine. He called them game-changers for depression and PTSD, especially for veterans.
This new push targets “our cherished veterans” suffering from severe mental illness.
Ibogaine comes from a plant and shows promise in early trials. A 2023 study by Stanford researchers found it cut opioid withdrawal symptoms in rats by 80%. Human tests lag behind due to strict rules.
The order directs agencies to speed approvals. Officials like HHS Secretary Robert F. Kennedy Jr. stood by, nodding support.
RFK Jr. has long backed natural treatments.
Key Figures Shape the Moment
Joe Rogan, a vocal cannabis fan, stood behind Trump. His podcast pushes legalization often. Guests like experts share stories of benefits.
Health Secretary Robert F. Kennedy Jr. leads HHS. He slammed past drug wars and favors reform.
CMS head Mehmet Oz and FDA Commissioner Marty Makary flanked the president. Oz has praised medical cannabis for pain on his shows.
Together, they form a team eyeing big changes in drug policy.
This lineup surprises some. It mixes media stars with doctors ready to act.
Cannabis Rescheduling: The Facts and Path Ahead
Rescheduling starts with HHS review. In real terms, the process reviews safety and medical value.
Here’s a quick look at drug schedules:
| Schedule | Abuse Risk | Medical Use | Examples |
|---|---|---|---|
| I | High | None | Heroin, LSD, Cannabis (current) |
| II | High | Yes, strict | Oxycodone, Methamphetamine |
| III | Medium | Yes | Ketamine, Anabolic steroids |
| IV | Low | Yes | Xanax, Valium |
| V | Lowest | Yes | Cough syrups with codeine |
Shifting cannabis to III would ease research taxes and open doctor prescriptions.
States like California see $5 billion in legal sales yearly, per 2023 state reports. National market hits $30 billion.
Doctors prescribe it now for epilepsy and nausea. More studies could prove pain relief too.
Opponents fear youth use spikes. CDC data shows teen use steady at 15% despite state laws.
What This Means for Everyday People
Lives hang in the balance. Patients wait for federal nods to access treatments without fear.
Vets with PTSD might pair cannabis with psychedelics for relief. Families save on black market buys.
Economy wins too. Jobs grow in farming and shops. A 2024 Leafly report counts 428,000 full-time roles.
Research speeds up. Universities test new strains without Schedule I blocks.
One sentence sums it up: Change feels close.
Trump’s words light a fire under slow bureaucrats.
This Oval Office nudge blends cannabis reform with psychedelics hope. It promises real relief for millions facing pain, addiction, and mental struggles. Trump’s firm push marks a turning point, easing old drug war rules for science and compassion to lead.
Maria Garcia is an award-winning author who excels in creating engaging cannabis-centric articles that captivate audiences. Her versatile writing style allows her to cover a wide range of topics within the cannabis space, from advocacy and social justice to product reviews and lifestyle features. Maria’s dedication to promoting education and awareness about cannabis shines through in her thoughtfully curated content that resonates with both seasoned enthusiasts and newcomers alike.
